advances of pd-1/pd-l1 inhibitors in tumor immunotherapy
Clicks: 242
ID: 247999
2017
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
6.6
/100
22 views
22 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Tumor immunotherapy, as one of the most promising research directions in the present field of oncotherapy, inhibits and kills tumor cells by enhancing anti-tumor immunity of the body. PD-1/PD-L1 inhibitors block negative control signals by inhibiting binding of PD-1 to its ligand PD-L1, leading to recovery of T cell activity and enhancement of immune response. In recent years, PD-1/PD-L1 inhibitors have shown good therapeutic effects in multiple tumor immunotherapies, making patients obtain long-term tumor remission and with controlled toxic and side effects. This article mainly reviewed the action mechanism and current situation of PD-1/PD-L1 inhibitors as well as their application effects in the treatment of various tumors.
| Reference Key |
liu2017journaladvances
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Yong-jun LIU;Yan ZHOU |
| Journal | The American journal of forensic medicine and pathology |
| Year | 2017 |
| DOI |
10.11910/2227-6394.2017.05.02.05
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.